论文部分内容阅读
目的 :检检测 5 7例乳腺浸润导管癌组织中cyclinD1基因的扩增和表达 ,并结合肿瘤大小、组织学分级、腋窝淋巴结转移和ER的表达进行临床病理预后分析。方法 :应用SP免疫组织化学及Southern杂交方法检测乳腺癌cyclinD1/CCND1基因的表达及扩增。结果 :显示 5 7例乳腺癌中 42例在瘤细胞核内有cyclinD1的表达。阳性率 73 6 % ,其中强阳性 11例 ,中阳性 14例 ,弱阳性 17例 ,阴性 15例。 16例乳腺癌中 2例有cyclinD1/CCDN1基因扩增。ER阳性率为 6 7%。结论 :cyclinD1的过度表达和扩增与肿瘤的大小和淋巴结转移及组织分级无关。ER和cyclinD1没有表达的病人可能预后差。乳腺癌的发生除与cyclinD1有关外可能还与其它癌基因及抑制癌基因如Rb、Bcl 2和ER等的协同作用有关。
Objective : To detect the amplification and expression of cyclinD1 gene in 57 invasive ductal carcinomas of the breast, combined with tumor size, histological grade, axillary lymph node metastasis and ER expression to analyze the clinicopathological prognosis. Methods: The expression of cyclinD1/CCND1 gene in breast cancer was detected by SP immunohistochemistry and Southern blotting. RESULTS: The expression of cyclinD1 in the tumor nucleus was found in 42 out of 57 cases of breast cancer. The positive rate was 73.6%, of which 11 were strongly positive, 14 were moderately positive, 17 were weakly positive, and 15 were negative. Two of 16 breast cancers had cyclinD1/CCDN1 gene amplification. The ER positive rate was 67%. Conclusion: The overexpression and amplification of cyclinD1 is not associated with tumor size, lymph node metastasis, and histological grade. Patients with no expression of ER and cyclinD1 may have poor prognosis. In addition to cyclinD1, the occurrence of breast cancer may also be related to the synergy of other oncogenes and inhibitors of oncogenes such as Rb, Bcl 2 and ER.